Author: Rossotti Roberto Moioli Maria Cristina Chianura Leonardo Errante Isabella Orcese Carloandrea Orso Maurizio Schiantarelli Clara Schlacht Irene Travi Giovanna Vigo Beniamino Villa Maria Riccarda Volonterio Alberto Puoti Massimo
Publisher: Informa Healthcare
ISSN: 0036-5548
Source: Scandinavian Journal of Infectious Diseases, Vol.44, Iss.11, 2012-11, pp. : 879-883
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Tenofovir disoproxil fumarate (TDF) is widely used in HIV-infected patients. It is associated with tubular toxicity, but its management is controversial. A possible strategy is to switch to a dual therapy based on lamivudine or emtricitabine (XTC) and protease inhibitors (PIs). A case–control study was designed to evaluate the switch to XTC + PI therapy in patients with TDF-related renal toxicity. A case was defined as a patient who was on TDF/XTC + PI and who switched to XTC + PI. A control was defined as a patient with the same clinical features who remained on TDF/XTC + PI. Twenty-one cases and 21 controls were included. After 48 weeks, no differences in efficacy were observed. No improvement in the glomerular filtration rate as estimated with the Cockroft–Gault formula (eGFR) was seen, but the number of times that patients had values below 60 ml/min was higher with standard TDF/XTC 1 PI treatment than with dual XTC + PI treatment. A switch to dual therapy could be an option for patients at risk of TDF-related renal damage with no relevant risk of virological or immunological failure.
Related content
Issue in statistical strategy in case‐control study
HEPATOLOGY, Vol. 62, Iss. 1, 2015-07 ,pp. :